Gene therapy and cervical cancer: An overview

CME Journal of Gynecologic Oncology

Volumn 6, Issue 3, 2001, Pages 377-382

  Huh, W K ^a   Alvarez, R D ^a   Curiel, D T ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

Cervical cancer; Gene therapy

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; PROTEIN BAX; PROTEIN BCL 2; PROTEIN P21; PROTEIN P53; VIRUS PROTEIN;

CANCER GENETICS; CANCER RESEARCH; FEMALE; GENE THERAPY; HUMAN; MEDICAL INFORMATION; MEDLINE; REVIEW; UTERINE CERVIX CANCER;

EID: 0035673894     PISSN: 12199087     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (69)

1. Cancer statistics, 2000
2. The epidemiology of human papillomavirus and cervical cancer
3. A papillomavirus DNA from cervical carcinomas and its prevalence in cancer biopsy samples from different geographic regions
4. Immortalization of primary human epithelial cells by cloned cervical carcinoma DNA containing human papillomavirus type 16 E6/E7 opening reading frames
5. The E6 and E7 genes of the human papillomavirus type 16 together are necessary and sufficient for transformation of primary human keratinocytes
6. Papillomaviruses and human cancer
7. Identification of early proteins of the papillomavirus type 16 (HPV 16) and type 18 (HPV 18) in cervical carcinoma cells
8. Interaction of the human papillomavirus type 16 E6 oncoprotein with wild-type and mutant human p53 proteins
9. Structure and transcription of human papillomavirus sequences in cervical carcinoma cells
10. Oncoproteins encoded by the cancer-associated human papillomavirus target the products of the retinoblastoma and p53 suppressor genes
11. Correlation of modified human papillomavirus early gene expression with altered growth properties in C4-1 cervical carcinoma cells
12. Antisense RNA. Its functions and applications in gene regulation - A review
13. Effect on cancer cells of plasmids that express antisense RNA of human papillomavirus type 18
14. Effects of human papillomavirus type-18-specific antisense oligonucleotides on the transformed phenotype of human carcinoma cell lines
15. Adenovirus-mediated transfer of HPV 16 E6/E7 antisense RNA to human cervical cancer cells
16. Efficiency of binding the retinoblastoma protein correlates with the transforming capacity of the E7 oncoproteins of the human papillomaviruses
17. Human papillomavirus 16 E6 expression disrupts the p53-mediated cellular response to DNA damage
18. Properties of p53 mutations detected in primary and secondary cervical cancers suggest mechanisms of metastasis and involvement of environment carcinogens
19. High-efficiency gene transfer and high-level expression of wild-type p53 in human lung cancer cells mediated by recombinant adenovirus
20. Growth suppression of human head and neck cancer cells by the introduction of a wild-type p53 gene via a recombinant adenovirus
21. Growth inhibition of human cervical cancer cells with recombinant adenovirus p53 in vitro
22. Adenovirus-mediated transfer of a wild-type p53 gene and induction of apoptosis in cervical cancer
23. Cloning of senescent cell-derived inhibitors of DNA synthesis using an expression screen
24. Differential regulation of cyclin A, cyclin B, and p21 concentrations in a growth-restricted human fibroblasts cell linc
25. p21 is a universal inhibitor of cyclin kinases
26. Subunit rearrangement of the cyclin-dependent kinases is associated with cellular transformation
27. WAF1, a potential mediator of p53 tumor suppression
28. In vivo gene therapy with p53 and p21 adenovirus for prostate cancer
29. Effects of ectopic overexpression of p21WAF1/CIP1 on aneuploidy and the malignant phenotype of human brain tumor cells
30. Tumor suppression by p21WAF1
31. Involvement of p53 and WAF1/CIP1 in γ-irradiation induced apoptosis of retinoblastoma cells
32. Inhibition of growth of human vascular smooth muscle cells by overexpression of p21 gene through induction of apoptosis
33. Up-regulated p21cip1 expression is part of the regulations quantitatively controlling serum deprivation-induced apoptosis
34. Adenovirus-mediated p21(WAF1/SDII/CIP1) gene transfer induces apoptosis of human cervical cancer cell lines
35. Bax-induced cell death may not require interleukin-1 beta-converting enzyme-like proteases
36. Heterodimerization with bax is required for Bcl-2 to repress cell death
37. Bax involvement in p53-mediated neuronal cell death
38. Bax suppresses tumorigenesis and stimulates apoptosis in vivo
39. Bax and adenine nucleotide translocator cooperate in the mitochondrial control of apoptosis
40. The bax gene, the promoter of apoptosis, is mutated in genetically unstable cancers of the colorectum, stomach, and endometrium
41. Proapoptotic gene bax is frequently mutated in hereditary non-polyposis colorectal cancers but not in adenomas
42. Bax frameshift mutations in cell lines derived from human haemopoietic malignancies are associated with resistance to apoptosis and microsatellite instability
43. Overexpression of bax sensitizes human breast cancer MCF-7 cells to radiation-induced apoptosis
44. An inducible recombinant adenoviral vector encoding bax selectively induces apoptosis in ovarian cancer cells
45. Efficient gene activation system on mammalian cell chromosomes using recombinant adenovirus producing Cre recombinase
46. A helper-dependent system for adenovirus vector production helps define a lower limit for efficient DNA packaging
47. Por-apopotic treatment with an adenovirus encording box enhances the effect of chemotherapy in ovarian cancer
48. An adenovirus encoding proapoptotic bax induces apoptosis and enhances the radiation effect in human ovarian cancer
49. Selectivity of action of an antiherpetic agent, 9-(2-hydroxyethoxymethyl) guanine
50. Inhibition by acyclovir of cell growth and DNA synthesis of cells biochemically transformed with herpes virus genetic information
51. Transduction of a drug-sensitive toxic gene into human leukemia cell lines with a novel retroviral vector
52. In vivo gene transfer with retroviral vector-producing cells for the treatment of experimental brain tumors
53. Systemic gene therapy of murine melanoma using tissue specific expression of the HSV-TK gene involves an immune component
54. Bystander killing of cancer cells by herpes simplex virus thymidine kinase gene is mediated by connexins
55. Adenoviral vectors capable of replications improve the efficacy of HSVtk/GCV suicide gene therapy of cancer
56. Human papillomavirus E6/E7-mediated adenovirus cell killing: Selectivity of mutant adenovirus replication in organotypic cultures of human keratinocytes
57. Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4
58. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long lasting anti-tumor immunity
59. Functional and molecular characterization of tumor-infiltrating lymphocytes transduced with tumor necrosis factor-DNA for the gene therapy of cancer in humans
60. Antimetastatic vaccination of tumor-bearing mice with two types of IFN-gamma gene-inserted tumor cells
61. A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes
62. Tumor rejection after direct costimulation of CD8+ T cells by B7-transfected melanoma cells
63. Cervical carcinoma cells transfected with the CD80 gene elicit a primary cytotoxic T lymphocyte response specific for HPV 16 E7 antigens
64. Adenoviral delivery of B7-1 (CD80) increases the immunogenicity of human ovarian and cervical carcinoma cells
65. Efficient lysis of CD44v7/8-presenting target cells by genetically engineered cytotoxic T-lymphocytes-A model for immunogene therapy of cervical cancer
66. Genetically modified bone marrow-derived dendritic cells expressing tumor-associated viral of "self" antigens induce anti-tumor immunity in vivo
67. Retroviral transduction of human dendritic cells with a tumor-associated antigen gene
68. Genetically modified dendritic cells as an effective vaccine in a murine model of human cervical cancer
69. Functional and molecular characterization of tumor-infiltrating lymphocytes transduced with tumor necrosis factor-alpha cDNA for the gene therapy of cancer in humans